ArticleScientific reports2025
Establishing and validating a new metabolic marker-driven prognosis signature for cutaneous melanoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative bioinformatic and experimental analysis reveals prognostic and immunological roles of psychological stress-related genes in skin cutaneous melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic reprogramming plays a critical role in the initiation and progression of skin cutaneous melanoma (SKCM). This study aims to construct a prognostic model based on metabolic-related genes (MRGs) to forecast patient outcomes and their response to immunotherapy. 10 machine learning algorithms within a cross-validation framework were utilized to compute prognostic risk scores based on MRGs, dividing SKCM patients into high- and low-risk groups. Further exploration included immune-related scores, immune infiltration levels, and oncological phenotype between these groups. The expression levels of six essential MRGs were assessed, and the effect of GALNT2 on proliferation and migration in SKCM cell lines was confirmed. This study has developed a new MRGs prognostic risk model that effectively predicts the survival of melanoma patients. The low-risk group exhibits higher immune scores and immune cell infiltration, which are beneficial for immunotherapy. In contrast, the high-risk group is positively correlated with the malignant phenotype of tumors, with increased MRG expression promoting tumor development. The study also identified six key genes, among which both the silencing and overexpression of GALNT2 significantly affect the proliferation and migration of melanoma cells. This study highlights the significance of MRGs in predicting patient survival and immunotherapy outcomes, providing insights for potential future targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.